|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wistuba II, Gazdar AF and Minna JD:
Molecular genetics of small cell lung carcinoma. Semin Oncol 28 (2
Suppl 4). S3–S13. 2001.
|
|
3
|
van Meerbeeck JP, Fennell DA and De
Ruysscher DK: Small- cell lung cancer. Lancet. 378:1741–1755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pelayo Alvarez M, Westeel V, Cortés-Jofré
M and Bonfill Cosp X: Chemotherapy versus best supportive care for
extensive small cell lung cancer. Cochrane Database Syst Rev.
CD0019902013.PubMed/NCBI
|
|
5
|
Shirasawa M, Fukui T, Kusuhara S, Hiyoshi
Y, Ishihara M, Kasajima M, Nakahara Y, Otani S, Igawa S, Yokoba M,
et al: Prognostic significance of the 8th edition of the TNM
classification for patients with extensive disease small cell lung
cancer. Cancer Manag Res. 10:6039–6047. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qiu G, DU X, Zhou X, Bao W, Chen L, Chen
J, Ji Y and Wang S: Prophylactic cranial irradiation in 399
patients with limited-stage small cell lung cancer. Oncol Lett.
11:2654–2660. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chan BA and Coward JI: Chemotherapy
advances in small-cell lung cancer. J Thorac Dis. 5 (Suppl
5):S565–S578. 2013.PubMed/NCBI
|
|
8
|
Oze I, Ito H, Nishino Y, Hattori M,
Nakayama T, Miyashiro I, Matsuo K and Ito Y: Trends in small-cell
lung cancer survival in 1993–2006 based on population-based cancer
registry data in Japan. J Epidemiol. Nov 17–2018.(Epub ahead of
print). doi: 10.2188/jea.JE20180112.
|
|
9
|
Harmsma M, Schutte B and Ramaekers FC:
Serum markers in small cell lung cancer: Opportunities for
improvement. Biochim Biophys Acta. 1836:255–272. 2013.PubMed/NCBI
|
|
10
|
Bremnes RM, Sundstrom S, Aasebø U, Kaasa
S, Hatlevoll R and Aamdal S; Norweigian Lung Cancer StudyGroup, :
The value of prognostic factors in small cell lung cancer: Results
from a randomised multicenter study with minimum 5 year follow-up.
Lung Cancer. 39:303–313. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ono A, Naito T, Ito I, Watanabe R, Shukuya
T, Kenmotsu H, Tsuya A, Nakamura Y, Murakami H, Kaira K, et al:
Correlations between serial pro-gastrin-releasing peptide and
neuron-specific enolase levels, and the radiological response to
treatment and survival of patients with small-cell lung cancer.
Lung Cancer. 76:439–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao WX and Luo JF: Serum neuron-specific
enolase levels were associated with the prognosis of small cell
lung cancer: A meta-analysis. Tumour Biol. 34:3245–3248. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sharma RA, Wotherspoon AC, Cook G, Morgan
GJ and Huddart RA: Neuron-specific enolase expression in multiple
myeloma. Lancet OncoL. 7:9602006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang L, Zhou JG, Yao WX, Tian X, Lv SP,
Zhang TY, Jin SH, Bai YJ and Ma H: Systematic review and
meta-analysis of the efficacy of serum neuron-specific enolase for
early small cell lung cancer screening. Oncotarget. 8:64358–64372.
2017.PubMed/NCBI
|
|
15
|
Molina R, Auge JM, Escudero JM, Marrades
R, Viñolas N, Carcereny E, Ramirez J and Filella X: Mucins CA 125,
CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with
lung cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour
Biol. 29:371–380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu S, Guo H, Kong L, Li H, Zhang Y, Zhu H
and Yu J: The prognostic factors in the elderly patients with small
cell lung cancer: A retrospective analysis from a single cancer
institute. Int J Clin Exp Pathol. 8:11033–11041. 2015.PubMed/NCBI
|
|
17
|
Buil-Bruna N, López-Picazo JM,
Moreno-Jiménez M, Martín-Algarra S, Ribba B and Trocóniz IF: A
population pharmacodynamic model for lactate dehydrogenase and
neuron specific enolase to predict tumor progression in small cell
lung cancer patients. AAPS J. 16:609–619. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fizazi K, Cojean I, Pignon JP, Rixe O,
Gatineau M, Hadef S, Arriagada R, Baldeyrou P, Comoy E and Le
Chevalier T: Normal serum neuron specific enolase (NSE) value after
the first cycle of chemotherapy: An early predictor of complete
response and survival in patients with small cell lung carcinoma.
Cancer. 82:1049–1055. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Zhang W, Yin W, Xiao Y, Zhou C, Hu
Y and Geng S: The prognostic value of the serum neuron specific
enolase and lactate dehydrogenase in small cell lung cancer
patients receiving first-line platinum-based chemotherapy. Medicine
(Baltimore). 96:e82582017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu S, Cai X, Xia L, Jiang C, Chen P, Wang
X, Zhang B and Zhao HY: Chloroquine exerts antitumor effects on NB4
acute promyelocytic leukemia cells and functions synergistically
with arsenic trioxide. Oncol Lett. 15:2024–2030. 2018.PubMed/NCBI
|
|
21
|
Liu X, Lv XB, Wang XP, Sang Y, Xu S, Hu K,
Wu M, Liang Y, Liu P, Tang J, et al: MiR-138 suppressed
nasopharyngeal carcinoma growth and tumorigenesis by targeting the
CCND1 oncogene. Cell Cycle. 11:2495–2506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lv XB, Jiao Y, Qing Y, Hu H, Cui X, Lin T,
Song E and Yu F: miR-124 suppresses multiple steps of breast cancer
metastasis by targeting a cohort of pro-metastatic genes in vitro.
CHIN J CANCER. 30:821–830. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan HJ, Tan Y and Gu W: Neuron specific
enolase and prognosis of non-small cell lung cancer: A systematic
review and meta-analysis. J BUON. 19:153–156. 2014.PubMed/NCBI
|
|
24
|
Proshchina AE, Krivova YS, Barabanov VM
and Saveliev SV: Ontogeny of neuro-insular complexes and islets
innervation in the human pancreas. Front Endocrinol (Lausanne).
5:572014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang D, Wang M, Sui A, Wang Y, Yang R,
Wang Z, Zhao Y, Jiao W and Shen Y: Prospective validation of
quantitative NSE mRNA in pleural fluid of non-small cell lung
cancer patients. Med Oncol. 30:6992013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jang SM, Kim JW, Kim CH, Kim D, Rhee S and
Choi KH: p19(ras) Represses proliferation of non-small cell lung
cancer possibly through interaction with Neuron-Specific Enolase
(NSE). Cancer Lett. 289:91–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gronowitz JS, Bergström R, Nôu E, Påhlman
S, Brodin O, Nilsson S and Källander CF: Clinical and serologic
markers of stage and prognosis in small cell lung cancer. A
multivariate analysis. Cancer. 66:722–732. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jett JR, Schild SE, Kesler KA and
Kalemkerian GP: Treatment of small cell lung cancer: Diagnosis and
management of lung cancer, 3rd ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest. 143
(Suppl 5):e400S–e419S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lurje G, Zhang W, Schultheis AM, Yang D,
Groshen S, Hendifar AE, Husain H, Gordon MA, Nagashima F, Chang HM
and Lenz HJ: Polymorphisms in VEGF and IL-8 predict tumor
recurrence in stage III colon cancer. Ann Oncol. 19:1734–1741.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ustuner Z, Saip P, Yasasever V, Vural B,
Yazar A, Bal C, Ozturk B, Ozbek U and Topuz E: Prognostic and
predictive value of vascular endothelial growth factor and its
soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small
cell lung cancer patients. Med Oncol. 25:394–399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Berx G and van Roy F: Involvement of
members of the cadherin superfamily in cancer. Cold Spring Harb
Perspect Biol. 1:a31292009. View Article : Google Scholar
|
|
33
|
Li LI, Lv Y, Zhang Y, He L and Zhang H:
Expression and clinical significance of Oct-4 and E-cad in
non-small-cell lung cancer. Oncol Lett. 11:234–236. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carotenuto M, de Antonellis P, Chiarolla
CM, Attanasio C, Damiani V, Boffa I, Aiese N, Pedone E, Accordi B,
Basso G, et al: A therapeutic approach to treat prostate cancer by
targeting Nm23-H1/h-Prune interaction. Naunyn Schmiedebergs Arch
Pharmacol. 388:257–269. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Esposito S, Russo MV, Airoldi I, Tupone
MG, Sorrentino C, Barbarito G, Di Meo S and Di Carlo E: SNAI2/Slug
gene is silenced in prostate cancer and regulates neuroendocrine
differentiation, metastasis-suppressor and pluripotency gene
expression. Oncotarget. 6:17121–17134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang CS, Shih MK, Chuang CH and Hu ML:
Lycopene inhibits cell migration and invasion and upregulates
Nm23-H1 in a highly invasive hepatocarcinoma, SK-Hep-1 cells. J
Nutr. 135:2119–2123. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim YI, Park S, Jeoung DI and Lee H: Point
mutations affecting the oligomeric structure of Nm23-H1 abrogates
its inhibitory activity on colonization and invasion of prostate
cancer cells. Biochem Biophys Res Commun. 307:281–289. 2003.
View Article : Google Scholar : PubMed/NCBI
|
